Also, TP53 and EGFR have been identified as one of several driver mutations in NSCLC (58), and were frequently detected in our lung cancer samples, indicating the reliability of our current WES study using cfDNA. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.